# Diabetes Research Hub — Monitor Report

**Run date:** 2026-04-28
**Monitor type:** Automated scheduled review (read-only)
**Hub root:** `C:\Users\justi\OneDrive\Diabetes_Research`
**Comparison window:** vs. 2026-04-21 (7d) and 2026-04-27 (1d) snapshots

---

## File System Status

All four primary data feeds are present and current.

| File | Last modified | Age | Status |
|---|---|---|---|
| `hub_monitor_report.md` | 2026-04-28 | 0d | Current |
| `clinical_trials_latest.json` | 2026-04-28 | 0d | Current |
| `pubmed_recent_latest.json` | 2026-04-28 | 0d | Current |
| `literature_gap_report.md` | 2026-04-27 | 1d | Current |
| `literature_gap_data.json` | 2026-04-20 | 7.7d | Current (gap matrix is regenerated weekly) |
| `clinical_trials_summary.md` | 2026-04-28 | 0d | Current |
| `pubmed_recent_summary.md` | 2026-04-28 | 0d | Current |
| `agent_state.json` | 2026-04-27 | 1d | Current |

The hub_monitor_report.md flags 499 result files older than 14 days, but these are dated snapshot files (e.g., `clinical_trials_snapshot_2026-03-15.json`) intended as historical record — not staleness. No action needed.

---

## Clinical Trial Changes

**Snapshot:** 773 unique trials today (up from 767 seven days ago, 771 yesterday).

### New trials since yesterday (2)
- **NCT07552389** — Hanlim Pharm. — Phase 3 RECRUITING — Monotherapy of HL111 in T2D
- **NCT05649137** — Novo Nordisk — Phase 3 COMPLETED — Semaglutide for excess weight + T2D (this trial is new to today's pull because it just transitioned to COMPLETED with results posted)

### Status changes (last 7 days)
- **NCT07400588** — Aleniglipron Phase 2 in T2DM: RECRUITING → ACTIVE_NOT_RECRUITING
- **NCT06993792** — Eli Lilly orforglipron master protocol (obesity ± T2D): RECRUITING → ACTIVE_NOT_RECRUITING (Phase 3)
- **NCT04061746** — MSC cellular therapy for T1D: RECRUITING → ACTIVE_NOT_RECRUITING

### Newly posted results (last 7 days) — high priority
| NCT | Sponsor | Phase | Posted | Trial |
|---|---|---|---|---|
| NCT05649137 | Novo Nordisk | Phase 3 | 2026-04-27 | Semaglutide in excess weight + T2D |
| NCT05971940 | Eli Lilly | Phase 3 | 2026-04-22 | Orforglipron in T2D adults |
| NCT05734989 | Duke | N/A | 2026-04-24 | Hispanic/Latinx CKD screening |
| NCT03898206 | Univ. of Bedfordshire | NA | 2026-04-21 | Breaking up prolonged sitting / postprandial cardiometabolic |
| NCT05144737 | Johns Hopkins | NA | 2026-04-22 | Afro-DPP virtual cardiometabolic program |

Both Phase 3 results (Novo Nordisk semaglutide + Lilly orforglipron) deserve immediate analyst review and incorporation into the tracker.

### Phase 3 RECRUITING — most recent of 44
The freshest active Phase 3 enrollments worth watching:
- **NCT07548996** — Dimethyl Fumarate in T1D adults (Nanjing Medical Univ., posted 2026-04-23) — repurposing signal
- **NCT07481747** — Tirzepatide vs placebo in adults with HbA1c not at goal (Hudson Biotech, 2026-03-19)
- **NCT07400653** — Pfizer PF-08653944 in obesity ± T2D (2026-02-10)
- **NCT07351058** — Roche enicepatide (RO7795068) in diabetes (2026-01-20)
- **NCT07258394** — Dimethyl Fumarate for islet β-cell preservation in T1D (2025-12-02) — companion to NCT07548996
- **NCT07088068** — Sanofi teplizumab Phase 3 vs placebo (2025-07-28) — PETITE-T1D follow-on
- **NCT06832410** — Vertex VX-880 Phase 3 in T1D
- **NCT07222332 / NCT07222137** — Eli Lilly baricitinib Phase 3 for β-cell preservation in children/adults (T1D)

### Key-organization snapshot
- **Vertex:** 3 trials — VX-880 Phase 3 (RECRUITING) and VX-264 Phase 1/2 (ACTIVE_NOT_RECRUITING).
- **Eli Lilly:** 27 trials — heavy GLP-1 / multi-agonist pipeline. Notable: orforglipron Phase 3 master protocol (NCT06993792) just moved to ACTIVE_NOT_RECRUITING; orforglipron T2D Phase 3 (NCT05971940) posted results 2026-04-22; baricitinib Phase 3 T1D pair recruiting; retatrutide three Phase 3 trials all ACTIVE_NOT_RECRUITING.
- **Novo Nordisk:** 23 trials — CagriSema Phase 3 expansion, weekly insulin icodec, oral semaglutide formulations, semaglutide T2D + excess weight Phase 3 just COMPLETED with results.
- **Sana Biotechnology:** 0 diabetes trials in current pull.

---

## PubMed Highlights

**155 unique papers** in 30-day rolling window (search corpus capped at 10/domain). +40 vs. yesterday, +104 vs. 7 days ago.

### Cross-domain papers (highest value — 6 total)
| PMID | Domains | Title |
|---|---|---|
| 41297910 | Key Therapy: orforglipron, retatrutide, CagriSema | Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolism (*Clin Mol Hepatol*, 2026-Apr) |
| 42041435 | T2D Remission, Diabetes AI/ML | Flexible wearable glucose sensor for noninvasive diabetes screening |
| 42038260 | Diabetes Microbiome, Diabetes Multi-Omics | Pathology, molecular mechanisms, and intervention strategies of cognitive dysfunction in diabetes |
| 42035781 | T1D Stem Cell Cure, T2D GLP-1 New | CGM vs. SMBG in individuals with T2D |
| 42032109 | Diabetes Gene Therapy, Diabetes Epigenetics | Cell-specific DNA methylation in human α and β cells regulates gene expression in T2D |
| 42023429 | T1D Immunotherapy, Diabetes Gene Therapy | CRISPR-based β-cell replacement and Treg immune modulation in T1D |

PMID 41297910 is the standout — it triangulates the three highest-priority Tier-3 multi-agonist therapies (orforglipron, retatrutide, CagriSema) and warrants a dedicated read.

### Key-therapy mention counts (last 30d)
| Therapy | Papers in corpus |
|---|---|
| orforglipron | 5 |
| retatrutide | 5 |
| dapagliflozin | 5 |
| teplizumab | 4 |
| baricitinib | 2 |
| CagriSema | 1 |
| icodec | 1 |
| zimislecel | 0 |

Notable papers worth analyst attention:
- 41992023 — Cardiometabolic profiles of oral vs. subcutaneous GLP-1 mono-agonists (*Diabetes Obes Metab*, 2026-Apr-16)
- 41984238 — Methodological/statistical inconsistencies in orforglipron efficacy/safety analyses (critique paper, *Acta Diabetol*)
- 42013280 — Improved conditioning for hematopoietic chimerism induces islet tolerance to cure diabetes (baricitinib mention, *JCI Insight*)
- 41785010 — Retatrutide in T2D + obesity overview (*Expert Rev Clin Pharmacol*)
- 39929732 — Clinical immunologic interventions for T1D (*Cold Spring Harb Perspect*, includes teplizumab)

### Domain volume
Search-result totals vary widely — the corpus cap of 10/domain hides differential activity. Highest-search-volume domains in the last 30 days: AI/ML (173), GLP-1 New (155), Biomarker (141), Microbiome (140). Smallest: GLP-1 Pharmacogenomics (1), LADA (4), Drug Repurposing (4) — these remain genuinely thin areas.

---

## Gap Analysis Summary

`literature_gap_data.json` (generated 2026-04-20, range 2020/01/01 → 2026/04/20). Top 5 ranked gaps with gap_score = 100:

| Rank | Domain pair | Joint pubs | Notes |
|---|---|---|---|
| 1 | Beta Cell Regen × Health Equity | 0 | Equity analysis of regenerative cell therapies entirely missing |
| 2 | Insulin Resistance × Islet Transplant | 1 | IR in transplant recipients affects graft survival but barely studied |
| 3 | Islet Transplant × GWAS / Polygenic | 0 | Methodologically distinct; lower priority |
| 4 | Islet Transplant × Personalized Nutr | 0 | Methodologically distinct |
| 5 | Islet Transplant × Drug Repurposing | 0 | Repurposed immunosuppressants for islet protection — high computational fit |

### Tier-1 alignment (per RESEARCH_DOCTRINE.md)
Several top gaps fall within our highest-value contribution areas:
- **Drug Repurposing (Tier 1 #4):** Islet Transplant × Drug Repurposing (rank 5), Glucokinase × Drug Repurposing, Drug Repurposing × Health Equity, Drug Repurposing × LADA — all gap_score 100.
- **Health Equity / Epidemiological (Tier 1 #6):** Beta Cell Regen × Health Equity (rank 1), Islet Transplant × Health Equity, Treg/CAR-T × Health Equity, Glucokinase × Health Equity, Health Equity × LADA — all gap_score 100.
- **Literature Synthesis (Tier 1 #2):** Gene Therapy × LADA, Personalized Nutr × LADA — both 100; LADA underdiagnosis remains a recurrent under-served angle.

These intersections are concrete leads for the next computational synthesis run.

---

## Breaking News (web search, last 7 days)

Three items rise above routine news:

1. **FDA expansion of Tzield (teplizumab) to children ≥1 year (2026-04-22)** — Sanofi sBLA approval extends T1D delay-of-onset indication from age 8+ down to age 1+, supported by 1-year PETITE-T1D Phase 4 data. Direct read-across to NCT07088068 (Sanofi teplizumab Phase 3 vs placebo, RECRUITING).
2. **Novo Nordisk PIONEER TEENS topline (2026-04-23)** — Phase 3a oral semaglutide superior to placebo on HbA1c in T2D ages 10–17. First oral GLP-1 RA pediatric pivotal. Regulatory filings expected H2 2026.
3. **Eli Lilly orforglipron (Foundayo) FDA approval (2026-04-01)** and follow-on Phase 3 results posting (NCT05971940, 2026-04-22) — both already reflected in the local trial database; the approval itself is not in clinical_trials_latest.json (which tracks trials, not regulatory actions) and should be logged in the tracker.

Generic dapagliflozin tablets (FDA, 2026-04-07) is also notable for cost-equity analysis — relevant to several Tier-1 Health Equity gaps above.

---

## Recommended Actions

1. **Update Diabetes_Research_Tracker.xlsx** with the three FDA actions (Tzield pediatric expansion, Foundayo approval, generic dapagliflozin) and add the two new Phase 3 results postings (NCT05649137, NCT05971940). Cite at Bronze/Silver evidence per Doctrine until peer-reviewed analyses publish.
2. **Read PMID 41297910** (multi-agonist precision targeting) — only paper in corpus tagged to all three of orforglipron / retatrutide / CagriSema; high cross-trial synthesis value.
3. **Read PMID 42032109** (α/β cell methylation in T2D) — sits at Gene Therapy × Epigenetics intersection and aligns with Tier-1 #1 (Multi-Omics Biomarker Integration).
4. **Pursue Drug Repurposing × Islet Transplant gap (rank 5)** — direct fit for Tier-1 #4. Two new Phase 3 dimethyl-fumarate trials (NCT07548996, NCT07258394) are the live evidence base; consider a formal repurposing screen against the islet survival target list in `islet_repurposing_targets.json`.
5. **Pursue Health-Equity gaps** — five separate intersections (Beta Cell Regen, Islet Transplant, Treg/CAR-T, Glucokinase, LADA) all show gap_score 100 vs. Health Equity. A single cross-domain equity synthesis paper would close multiple gaps simultaneously and aligns with Tier-1 #6.
6. **Refresh literature gap analysis** — `literature_gap_data.json` is 7.7 days old. Consider re-running `python project1_literature_gap_analysis.py` after this week's PubMed pulls to capture the +104 new papers.
7. **Track Sanofi teplizumab Phase 3 NCT07088068** — given the 2026-04-22 PETITE-T1D-derived FDA expansion, the parallel Phase 3 vs. placebo trial just gained strategic context. Add to "Notable Trials to Watch" in clinical_trials_summary.md (currently empty).
8. **No script reruns required.** All four feeds (hub_monitor, clinical_trials, pubmed_recent, literature_gap) are present and recent.

---

*Generated by automated diabetes-hub-monitor task — 2026-04-28*
